Overview Request Sample Pages Request Customization Download PDF
You are viewing: UK Gene Expression Analysis Market analysis

The UK Gene Expression Analysis Market was valued at $227.3 Million in 2026 and projected to reach to $331.2 Million by 2031, representing a compound annual growth rate of 7.8%. The UK gene expression analysis market is positioned for sustained growth through 2031, driven by the NHS's commitment to precision medicine and increasing adoption of genomic testing in routine clinical practice.

UK Gene Expression Analysis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Gene Expression Analysis Market Trends and Insights

  • The UK market is driven by increasing adoption of precision medicine, rising investment in genomic research, and growing demand for personalized healthcare solutions across NHS and private institutions.
  • The UK's strong regulatory framework and advanced research infrastructure position it as a leading hub for gene expression technologies in Europe. The UK gene expression analysis market benefits from substantial government funding for life sciences research and a highly skilled workforce in molecular biology and bioinformatics.
  • Between 2026 and 2031, the UK is expected to see accelerated adoption of RNA sequencing and digital pathology solutions in clinical diagnostics and drug development.
  • The UK's commitment to genomic medicine initiatives and partnerships between academic institutions and biotechnology firms further support market expansion during the forecast period..

Key Market Statistics

  • CAGR (2026-2031) 7.8% CAGR
  • Market Size, 2026 ~USD 227.3 Million
  • Forecast, 2031 ~USD 331.2 Million
  • Country UK

UK Gene Expression Analysis Market Overview

Market Valuation Growth :

The UK gene expression analysis market is valued at £227.3 million in 2026 and is projected to reach £331.2 million by 2031, representing a robust CAGR of 7.8% over the forecast period.

NHS and Private Sector Adoption :

Increasing integration of gene expression analysis across NHS trusts and private healthcare institutions is driving market expansion, with growing demand for precision diagnostics and personalized treatment protocols.

Genomic Research Investment :

UK government and institutional funding for genomic research initiatives, including the 100,000 Genomes Project legacy, continues to accelerate adoption of advanced gene expression technologies across research and clinical settings.

Regulatory Framework Advantage :

The UK's established regulatory environment and MHRA oversight provides a competitive advantage for gene expression analysis providers, facilitating faster market entry and clinical validation of innovative diagnostic solutions.

UK Gene Expression Analysis Market Dynamics

  • Healthcare providers are investing in advanced molecular diagnostics to improve patient outcomes and reduce treatment costs, particularly in oncology, rare disease diagnosis, and pharmacogenomics.
  • The convergence of declining sequencing costs, improved bioinformatics capabilities, and supportive regulatory policies creates a favorable environment for market expansion.
  • Private healthcare providers and academic medical centres are also accelerating their adoption of gene expression platforms, complementing NHS initiatives and broadening market reach across the UK..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Qiagen N.V.
  • Agilent Technologies, Inc.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • The UK gene expression analysis market is valued at £227.3 million in 2026 and will reach £331.2 million by 2031, representing a 7.8% CAGR.
      • The UK market is driven by precision medicine adoption, NHS genomic initiatives, and increased investment in personalized healthcare across the country.
      • The UK's advanced research infrastructure and regulatory environment position it as a leading European hub for gene expression technology innovation.
      • Between 2026 and 2031, the UK will experience accelerated adoption of RNA sequencing and digital pathology in clinical diagnostics and pharmaceutical development.

      Gene Expression Analysis Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment ASSAYS & KITS (Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 7% from 2026 to 2031
      Largest Segment REAGENTS & CONSUMABLES (Offering)
      Market Size Base Year (Billions) ~USD 4.23 (2026)
      Revenue Forecast (Billions) ~USD 5.93 (2031)
      Segments Covered Offering, Type

      UK Gene Expression Analysis Market Report Segmentation

      2 segment dimensions are covered across the global market.

      By Offering

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Type

      • Assays & Kits
      • Bioinformatics & Data Analysis Services
      • Bioinformatics Solutions
      • Cdna Synthesis Kits
      • Cloud-Based Analysis Platforms
      • Data Analysis Software & Visualization Tools
      • Dna Chips
      • Dna Microarray Scanners
      • Enzymes
      • Gene Expression Analysis
      • Gene Expression Databases
      • Library Preparation Kits
      • Microarray Analysis Services
      • Ngs Instruments
      • Other Assays & Kits
      • Other Gene Expression Services
      • Other Instruments
      • Other Reagents & Consumables
      • Pcr Assays & Kits
      • Pcr Instruments
      • Qpcr Profiling Services
      • Rna Isolation Kits
      • Rna Sequencing Services
      • Software

      UK: GENE EXPRESSION ANALYSIS MARKET, BY END USER, 2024–2031

      Segment20242025202620272028202920302031CAGR (%)
      ACADEMIC & RESEARCH INSTITUTES44.246.549.452.756.360.465.170.47.4
      CROS30.432.334.737.440.443.847.6528.4
      HOSPITALS & CLINICAL LABORATORIES40.743.446.750.554.759.564.971.18.8
      OTHER END USERS10.710.81111.211.411.611.912.12
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES75.880.185.691.898.7106.5115.4125.58
      TOTAL201.9213.2227.3243.6261.5281.8304.9331.27.8

      Target Audience

      • Diagnostic Device Manufacturers : Need UK market intelligence to develop go-to-market strategies, identify NHS procurement pathways, and understand competitive positioning for gene expression analysis platforms in the British healthcare system.
      • Healthcare Providers and NHS Trusts : Require market data to justify investment in gene expression testing infrastructure, benchmark adoption rates against peers, and align genomic medicine strategies with NHS precision medicine initiatives.
      • Pharmaceutical and Biotech Companies : Seek UK-specific insights on companion diagnostic opportunities, pharmacogenomics adoption, and precision medicine trends to inform drug development and clinical trial strategies in the UK market.
      • Investment and Private Equity Firms : Need comprehensive UK market analysis to evaluate investment opportunities in gene expression diagnostics, assess growth potential, and identify acquisition targets within the British healthcare sector.
      • Research Institutions and Academic Centres : Require market data to understand commercialization opportunities, identify funding trends, and benchmark their genomic research capabilities against UK market developments and clinical adoption patterns.

      Key Companies in the UK Gene Expression Analysis Market

      CompanyHQOwnershipStrongest segments
      ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanyCustom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions,
      DECODE GENETICSIcelandPrivate CompanyInternal Amgen discovery and target validation programs,External research collaborations and grants,Commercial genomics and analytics services,
      GENOMIC HEALTH INCUnited StatesPrivate CompanyOncotype DX Breast Recurrence Score and related breast assays,Oncotype DX Colon and other solid tumor assays,Emerging decision-support and ancillary genomic services,
      TRANSGENOMIC, INC.United StatesPublic CompanyGenetic analytical and pharmacogenomics research services,Multiplexed ICE COLD-PCR reagents and consumables,Other genomic testing and platform technologies (ICE COLD-PCR, cfDNA, CTC assays),
      UNILABSSwitzerlandPrivate CompanyRoutine & specialised laboratory testing,Medical imaging,Pathology & centres of excellence,
      MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Processing assemblies (PAs) and consumables,Licensing and technology access fees,
      GENERAL ELECTRICUnited StatesPublic CompanyCommercial Engines & Services,Defense & Propulsion Technologies,Aircraft Components and Systems (Avio Aero, Unison, Dowty, Colibrium Additive),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyLife Science segment,Clinical Diagnostics segment,
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (immune response, oncology, sexual and reproductive health),Research PCR and enzymes (qPCR, digital PCR, RT-PCR),
      REVVITYUnited StatesPublic CompanyDiagnostics (prenatal, neonatal, infectious disease, immunodiagnostics),Life Science Reagents & Assays (BioLegend, Dharmacon, AlphaLISA, etc.),Instruments & Imaging Systems,
      PACBIOUnited StatesPublic CompanyLong-read instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read (Onso platform and reagents),
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation diagnostics,Blood gas, electrolyte, and urinalysis systems,
      EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma Services,
      STANDARD BIOTOOLSUnited StatesPublic CompanyProteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and related systems),Services, software, and other,
      OXFORD NANOPORE TECHNOLOGIES PLCUnited KingdomPublic CompanyMinION and portable platforms (incl. Mk 1D),GridION / GridION Q benchtop systems,PromethION (P2, P24, P48) high-throughput,
      GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
      TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,PCR instruments and cellular analysis devices,In vitro diagnostics (including COVID-19 testing),

      ATS AUTOMATION TOOLING SYSTEMS INC

      ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.

      DECODE GENETICS

      Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company operates in the genetics and genomics sector.

      GENOMIC HEALTH INC

      Genomic Health Inc. is a private United States company founded in 2000 with 829 employees. The company focuses on genomic testing and personalized medicine.

      TRANSGENOMIC, INC.

      Transgenomic, Inc. is a public United States company founded in 1997 with 19 employees. The company operates in the genomics and molecular diagnostics field.

      UNILABS

      Unilabs is a private Swiss company founded in 1987 with 1,897 employees. The company provides laboratory and diagnostic services.

      MAXCYTE, INC

      MaxCyte, Inc. is a public United States company founded in 1998 with 91 employees. The company develops cell engineering technologies.

      GENERAL ELECTRIC

      General Electric is a public United States company founded in 1892 with 57,000 employees. The company operates across multiple industrial and technology sectors.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a public United States company founded in 1956 with 125,000 employees. The company is a global leader in life sciences, analytical instruments, and laboratory services.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a public United States company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.

      ILLUMINA, INC.

      Illumina, Inc. is a public United States company founded in 1998 with 8,625 employees. The company is a leading provider of DNA sequencing and genetic analysis technologies.

      QIAGEN

      QIAGEN is a public company founded in 1984 in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences products.

      REVVITY

      Revvity is a public United States company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for research and diagnostics.

      PACBIO

      PacBio is a public United States company founded in 2000 with 485 employees. The company develops long-read DNA sequencing technologies.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a public United States company founded in 1999 with 18,000 employees. The company manufactures analytical instruments, software, and services for life sciences and diagnostics.

      SYSMEX CORPORATION

      Sysmex Corporation is a public Japanese company founded in 1968 with 10,861 employees. The company manufactures and sells in vitro diagnostic systems and laboratory instruments.

      EUROFINS SCIENTIFIC

      Eurofins Scientific is a public company founded in 1987 in Luxembourg with 65,694 employees. The company is a leading provider of laboratory testing and analytical services globally.

      STANDARD BIOTOOLS

      Standard Biotools is a public United States company founded in 1999 with 387 employees. The company develops microfluidics and cell analysis technologies.

      OXFORD NANOPORE TECHNOLOGIES PLC

      Oxford Nanopore Technologies PLC is a public United Kingdom company founded in 2005 with 1,316 employees. The company develops nanopore-based DNA and RNA sequencing technologies.

      GENSCRIPT

      GenScript is a public company founded in 2002 in Hong Kong with 6,165 employees. The company provides biotechnology research services and products including gene synthesis and protein production.

      TAKARA BIO INC.

      Takara Bio Inc. is a private Japanese company founded in 2002 with 1,779 employees. The company manufactures and sells molecular biology reagents and research products.

      Reasons to Buy this Report

      • UK-Specific Market Sizing : Access precise valuation data for the UK market (£227.3M in 2026) with detailed forecasts through 2031, enabling accurate budget allocation and revenue projections for UK-focused business strategies.
      • NHS Integration Insights : Understand adoption patterns across NHS trusts and private institutions, identifying key procurement opportunities and partnership pathways within the UK's unique healthcare ecosystem.
      • Regulatory and Compliance Guidance : Gain clarity on UK-specific regulatory requirements, MHRA approval pathways, and compliance frameworks essential for launching or expanding gene expression analysis solutions in the British market.
      • Competitive Landscape Analysis : Identify key UK market players, emerging competitors, and market share dynamics to inform competitive positioning and differentiation strategies tailored to the UK healthcare environment.
      • Growth Driver Identification : Leverage detailed analysis of UK-specific growth catalysts including genomic research funding, precision medicine initiatives, and healthcare provider investment trends to capitalize on market opportunities.

      Frequently asked questions

      What is the current size of the UK gene expression analysis market?

      The UK gene expression analysis market is valued at £227.3 million in 2026 and is projected to grow to £331.2 million by 2031.

      What is the growth rate of the UK gene expression analysis market?

      The UK gene expression analysis market is growing at a compound annual growth rate (CAGR) of 7.8% from 2026 to 2031.

      What are the main drivers of growth in the UK market?

      Key drivers include increasing adoption of precision medicine, NHS genomic medicine initiatives, rising investment in personalized healthcare, and strong government funding for life sciences research.

      Which technologies are driving adoption in the UK?

      RNA sequencing, digital pathology solutions, and advanced bioinformatics platforms are the primary technologies accelerating market growth in the UK between 2026 and 2031.

      How does the UK market compare to other European markets?

      The UK's advanced research infrastructure, regulatory framework, and government commitment to genomic medicine position it as a leading European hub for gene expression analysis technologies.

      RESEARCH METHODOLOGY

      This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global gene expression analysis market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the gene expression analysis market. The secondary sources used for this study include World Health Organization (WHO), Food and Drug Administration (FDA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Environmental Protection Agency (EPA), European Medicines Agency (EMA), Biotechnology Innovation Organization (BIO), International Society for Pharmaceutical Engineering (ISPE), National Institute for Health and Care Excellence (NICE), World National Center for Biotechnology Information (NCBI), International Trade Centre, Journal of Molecular Biology, Journal of Biological Chemistry (JBC), American Association for Cancer Research (AACR), the American Society of Human Genetics (ASHG), and the European Molecular Biology Organization (EMBO). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations, among others.

      Secondary data were collected and analyzed to determine the overall size of the global gene expression analysis market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Gene Expression Analysis Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the gene expression analysis market. These methods were also used extensively to estimate the size of various market segments.

      Gene Expression Analysis Market : Top-Down and Bottom-Up Approach

      Gene Expression Analysis Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Gene expression analysis is the systematic investigation of the activity levels of genes within a cell, tissue, or organism at a specific point in time, which involves measuring & quantifying the production of RNA or protein molecules encoded by genes that reflect the degree to which genes are being transcribed and translated into functional products. In gene expression analysis, we use products & services related to the analysis and measurement of gene expression. This market includes gene expression analysis products & services such as reagents & consumables, instruments, gene expression analysis services, and bioinformatics solutions.

      Key Stakeholders

      • Pharmaceutical & biotechnology companies
      • Contract research organizations (CROs)
      • Life science companies
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the gene expression analysis market based on offering, application, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall gene expression analysis market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the gene expression analysis market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the gene expression analysis market
      • To benchmark players within the gene expression analysis market using the ‘Company Evaluation Matrix’ framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Customization Options

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Geographical Analysis

      • Further breakdown of the Rest of Europe gene expression analysis market, by country
      • Further breakdown of the Rest of Asia Pacific gene expression analysis market, by country
      • Further breakdown of the Rest of Latin America gene expression analysis market, by country
      • Further breakdown of the Rest of Middle East gene expression analysis market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Gene Expression Analysis Market Report

      Full forecast, segment splits, and company analysis for all Gene Expression Analysis Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status